PhRMA Urges FDA To Set Non-Inferiority Margin For Skin Infection Drugs

FDA should provide more specificity on the non-inferiority margin it expects clinical trials for acute bacterial skin and skin structure infection (ABSSSI) treatments to satisfy, pharmaceutical companies and infectious disease specialists say.